FDA staffers back efficacy of Novartis’ Enbrel biosimilar
US Food and Drug Administration staffers have concluded that Sandoz’ biosimilar of Amgen’s blockbuster Enbrel, dubbed GP2015, is “highly similar” to its reference product, pushing the drug closer to approval.
Read More
